Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.
Study Type
OBSERVATIONAL
Enrollment
2,105
Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD)
Time frame: 5 years
Compare the incidence of selected morbidities among three groups of patients with ESRD
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Research Center, Inc.
Birmingham, Alabama, United States
Clinical Research Consultants
Hoover, Alabama, United States
University of South Alabama
Mobile, Alabama, United States
Montgomery Kidney Specialists
Montgomery, Alabama, United States
California Kidney Specialist
Covina, California, United States
Atlantic Avenue Medical Clinic
Cudahy, California, United States
East Bay-South Hayward Dialysis Center
Hayward, California, United States
Renal Research Center
Los Alamitos, California, United States
USC Kidney Center
Los Angeles, California, United States
Beverly Nephrology
Los Angeles, California, United States
...and 189 more locations